XSHG
603229
Market cap999mUSD
Oct 09, Last price
8.19CNY
1D
1.61%
1Q
1.24%
IPO
117.82%
Name
Zhejiang Ausun Pharmaceutical Co Ltd
Chart & performance
P/E
52.08
P/S
8.64
EPS
0.16
Div yield, %
1.24%
Shrs. gr., 5y
9.59%
Rev. gr., 5y
13.97%
Revenues
787m
-1.07%
Net income
131m
-36.86%
CFO
157m
-12.04%
Dividend
Jul 17, 20260.064 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 2010 and headquartered in Linhai, China, Zhejiang Ausun Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of unique active pharmaceutical ingredients (APIs) and various intermediate compounds for drug synthesis. Its comprehensive portfolio includes fluorine-based compounds, prostaglandins, and anti-infectives, in addition to critical oncology therapeutics. The company also provides medications targeting liver, respiratory, cardiovascular, and cerebrovascular conditions, as well as central nervous system (CNS) disorders. Furthermore, Zhejiang Ausun Pharmaceutical is involved in contract processing services and continuous scientific research and development initiatives.
Key people
Dingmin Zhu
Chief Financial Officer · since 2021
Zhiguo Zheng
Chairman of the Board, General Manager · since 2014
Kai Gao
Deputy General Manager · since 2020
Jiguo Song
Deputy General Manager · since 2023
Yu Zhong
Deputy General Manager · since 2020
Xiaochen Ying
Secretary of the Board · since 2021
Fei Chen
Director · since 2015
Yu Liu
Director · since 2020
Huadong Zhang
Director, Deputy General Manager · since 2014
Shilan Zheng
Director · since 2014
Hemin Zhu
Director · since 2023
Mingmin Luo
Independent Director · since 2020
Yuanjiang Pan
Independent Director
Independent Director · since 2023
Shuxing Yang
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||